NTU Centers of Genomic and Precision Medicine (CGPM) is committed to contributing abundant research achievement to our society. The primary feature of CGPM is the platform-based integration of basic research and clinical studies in translational medicine, in conjunction with the momentum of NTU’s medical system and the biomedical industry. Under the COVID-19 pandemic, CGPM actively participates in topics related to policy development and clinical treatment. It pioneers to work on SARS-CoV-2 whole genome sequencing and phylogenetic analysis, in order to identify the possible origins and transmission pathways of the viral strain. Let's join Office of International Affairs for a virtual tour to CGPM and unveil its mystery together! About CGPM CGPM leverages multiple omics research methods to address three unmet medical needs: Infection Disease , Stress Biology , and Cancer. It aims to reduce incidence rates and fatality rates in infectious diseases and cancers, and propose targeted treatment plans for individual or racial variations. With resources and expertise in multiomics, bioinformatics, and structural biology, CGPM has formed a solid scientific platform with cross-border academic collaboration. Features The core labs cover about 11,570 square meters. With core labs and biomedical resources, CGPM is a top research center integrating translational medicine and multiomics in Taiwan. While Genomic Research Center at Academia Sinica is larger in size (over 23,000 square meters in floor area), it only focuses on basic research. It is rare in Asia for universities to establish such a research center along with clinical medicine. Within CGPM, 48% of members are healthcare professionals with clinical backgrounds. Throughout the years, CGPM and College of Medicine have been facilitating international collaboration. Over 100 scholars and experts, and several university presidents have visited from Europe, America, and Japan, and all acknowledged it is a great model for emulation. NTU is committed to educating top-notched researchers and leaders. CGPM has adopted multiple approaches for undergraduates, graduate students, postdocs, and faculty. By working with NTU Promotion Center of Precision Medicine, NTU SPARK, BioGroup, and NTU Center for Biotechnology, CGPM has organized programs for 500 physicians, scholars, postgraduates, and college students from NTU and beyond. It’s an effort to build up a biomedicine ecosystem on campus. Over the past five years, CGPM has trained 622 postgraduate students, and recruited 181 high-level researchers. It has also published 323 academic papers in international journals, including 71 high-impact ones. During the same period, there has been 31 (18 local and 13 international) collaborative studies between industries and research labs. Industrial players have contributed over NT$50 million in these projects. CGPM also engages with multiple international projects, such as a cancer research center with MD Anderson Cancer Center in America, and TRANSCAN with France, Italy, and Belgium. It aspires to become a representative and primary collaborator on behalf of NTU and medical research in Taiwan. Research Highlights Future Tech Award at 2022 Taiwan Innotech Expo CGPM exhibited the research results at 2022 Taiwan Innotech Expo and received Future Tech Award with “cell-free virus-host chimera DNA from hepatitis B virus integration sites as a circulating biomarker for monitoring hepatocellular carcinoma”. Cancer Moonshot Project Since 2016, CGPM has participated in Taiwan Cancer Moonshot Project executed by Academia Sinica, as one of the founding members in Cancer Moonshot project initiated by National Cancer Institute in the U.S. In 2020, the Cell journal introduced efforts by NGS & Microarray Core Lab of CGPM in Cancer Moonshot in its cover story. Founded in 2000, NGS & Microarray Core Lab is the earliest genome translational research lab in Taiwan. It was ISO15189 certified from 2013 to 2020. In 2022, it was LDTS certified by Ministry of Health and Welfare. Its major research highlights include: It is responsible for specimen storage, clinical data compilation, as well as whole genome, whole exome, and whole transcriptome sequencing. Results contribute to Taiwan Cancer Precision Medicine Database. It is available for cancer gene big data development in academic and industrial purposes. It also receives three project funding from National Science and Technology Council. In the first and second phases of Cancer Moonshot, CGPM has included the key and unique cancer types in Taiwan, including lung cancer, breast cancer, gastric cancer, multiple primary lung cancer, ovarian cancer, and pancreatic cancer. NCI in America invites NGS & Microarray Core Lab to collaborate with University of Washington, University of Rochester Medical Center, Fred Hutchinson Cancer Research Center, and NTU. The project targets Thyroglobulin (Tg), and uses mass spectrometry to quantify how antibodies in blood interfere to immunotherapy. With references from Clinical Laboratory Improvement Amendments in America, it tests mass spectrometry methods established by American teams in Taiwan. With specimens from thyroid cancer patients, it verifies Tg levels and cancer diagnosis capabilities. Based on Ministry of Health and Welfare requirements, it has established Tg test standards specific to Taiwan, and applied for LDTS certification. Developing Global Vision from Taiwan Precision medicine research involves high-throughput technologies and the processing of tremendous data. It is critical for CGPM to foster interdisciplinary collaboration between molecular biology, biochemistry, multiomics, structural biomedicine, bioinformatics, and smart healthcare. The team includes core multiomics labs in CGPM, labs in NTU College of Medicine, and clinical trial capabilities in NTU Hospital. CGPM utilizes basic science and new technologies to transform traditional methodologies. Interdisciplinary studies with multiple perspectives focus on nosogenesis, drug development, and early diagnosis. It is committed to training high-level researchers with international views and expertise, especially in precision medicine. These efforts will elevate Taiwan in international fields, and increase values to industries. CGPM members comprise researchers from several NTU colleges, including College of Electrical Engineering & Computer Science, College of Life Science, College of Bio-Resources & Agriculture, and College of Public Health. Along with NTU Joint Research Center for AI Technology and All Vista Healthcare founded in 2018, and Quanta AI Computing Room at NTUH Center of Intelligent Healthcare founded in 2022, we’ve combined healthcare big data, AI, superior computing, and storage systems to address patient privacy, ethics, and data security issues. This also helps position NTU Hospital as a new healthcare paradigm. Governments in Taiwan invest in niche precision medicine, and Bio Taiwan Committee recommends to integrate biomedicine and smart technologies for precision healthcare. CGPM will continue to integrate resources on and off campus. We work with the NTU Hospital system, including Clinical Trial Center, NTU Cancer Center, and NTUH Biomedical Park Hospital, as well as NTU biomedicine ecosystem. This partnership enables an interdisciplinary platform, and contributes to a leading and competitive precision medicine research center in the world, together with different parties to create a better future for precision medicine!
國立 臺灣大學基因體暨精準醫學研究中心 (NTU CGPM）致力將豐碩研究成果奉獻於社會，研究中心最大特色在於平台式融入轉譯醫學之基礎與臨床研究，並有效結合臺大醫療體系與生醫產業力量。且研究中心積極參與新興新冠肺炎疫情之政策擬定及臨床治療等議題，率先進行SARS-CoV-2新冠病毒株全基因體定序及親源分析，釐清各新冠病毒株可能源起及傳播途徑。 國際事務處將帶領大家一同探索精準醫學研究中心，揭開其奧秘面紗！ 中心簡介 精準醫學研究中心運用多種體學方法，深入了解感染症、逆境醫學及癌症等三大臨床未解之需求，以降低感染症和相關癌症發生率與致死率為研究主軸，針對相關疾病提出更精確的治療方案，應對疾病成因在個人及種族上差異。並透過既有多體學資源，結合資訊與結構生物學專業，組成團體科學合作平台，架起學術合作無國界窗口。 中心優勢 中心硬體方面核心實驗室空間約3,500坪，並整合各核心實驗室與生醫資源，為全臺第一醫學領域、多體學相關綜合研究中心。唯一比臺大更具規模的是設置在中研院的國家基因體研究中心(超過23,000平方公尺，但只著重於基礎研究)。目前在亞洲各大學能夠成功結合臨床醫學中心之同類型研究中心非常少，而研究中心特色之一即為中心成員約48% 具有臨床專業的醫事人員。研究中心與醫學院長期以來共同促進國際學術合作，陸續接待超過百位以上之歐美日等國際重要學者專家及數位世界知名大學校長，參訪研究中心後均一致讚賞肯定，認為值得仿效。 人才培育部份，高階研發與領導人才的養成是國立臺灣大學的使命，也是責無旁貸的工作。研究中心對於高階研究人才的培育從數個層面著手，由大學生、研究生、博士後研究人員到教師各有不同之方案與計畫。透過與臺大精準醫學推動中心、NTU SPARK、BioGroup計畫及臺大生技中心合作，培育校內外醫師學者碩博大學生團隊超過500人次，持續建立校園生醫生態系。近五年研究中心培育碩博士學生共622位、延攬高階研發人才共181位。於學術研究之面向，近五年共發表323篇國際期刊論文，含高影響論文71篇。研究中心近五年促成產業/學界合作研究共計31件，含國內18件與國外13件，國內外合作廠商配合款逾新台幣五千萬元；研究中心積極承接國際合作計畫，包括與美國MD Anderson Cancer Center 合作之「跨國頂尖癌症研究中心」、與歐洲法國、義大利、比利時合作之TRANSCAN 計畫等，期許成為不僅代表臺灣大學，更足以代表臺灣醫學及醫療研究領域的國際特色代表中心與合作櫥窗。 研究亮點 2022年台灣創新技術博覽會未來科技館-榮獲「未來科技獎」 精準醫學研究中心亮點技術於2022年「台灣創新技術博覽會未來科技館」參與展出，其中「開發“病毒宿主嵌合DNA”為B型肝炎病毒相關肝癌之血液腫瘤標記」之技術，榮獲「未來科技獎」。 癌症登月計畫 研究中心自2016年起即參與中央研究院執行的台灣癌症登月計畫，成為美國癌症中心國際癌症登月計畫的起始會員之一。2020年，中心所屬「新一代定序與微陣列核心實驗室」與美國共同研究的癌症登月計畫更是榮登《細胞》期刊 (Cell)封面。 「新一代定序與微陣列核心實驗室」成立於2000年，為台灣最資深的基因體醫轉譯研究實驗室，並於2013-2020年取得ISO15189醫學認證實驗室，2022年通過衛福部食藥署精準醫學分子檢測實驗室(LDTS)認證。主要研究重點包括： 負責檢體儲存與臨床資料彙整、全基因組、全外顯子與全轉錄體等定序相關實驗，最終完成「台灣癌症精準醫療智識庫」，提供產官學研界進行癌症蛋白基因大數據研究開發之用，並通過三件國科會專案研究計畫。 於第一期與第二期登月計劃納入台灣重要與獨特的癌症進行研究，包括肺癌、乳癌、胃癌、多重原發性肺癌、卵巢癌、胰臟癌。 美國NCI邀請我方與美國University of Washington、University of Rochester Medical Center、Fred Hutchinson Cancer Research Center及臺大合作，以現行甲狀腺癌標記分子Thyroglobulin (Tg)為標靶，以質譜檢測可提升血液中抗體對免疫方法造成干擾之定量正確性，借鏡美國採用之Clinical Laboratory Improvement Amendments (CLIA)規範，同步於台灣試行美國團隊建立之質譜檢測方法，在台灣甲狀腺癌病人檢體中驗證標靶分子Tg之濃度與其癌症診斷能力，並依據衛福部特管辦法，建立台灣專屬的甲狀腺癌Tg檢測標準並申請LDTS認證中。 立足臺灣，放眼全球 精準醫學研究涉及高通量技術及巨量數據處理，透過研究中心之設置整合分子生物、生物化學、多體學、結構生醫學，生醫資訊學、及智慧醫學等跨領域、跨單位交流合作即成為必要手段。 藉由研究中心既有核心實驗室多體學資源與臺大醫學院共同研究室支援，結合臺大醫院頂尖臨床研究能量與臨床試驗中心，組成堅實團體科學平台。研究中心將能夠以基礎科學思維及新式技術平台顛覆傳統單向研究思維，並以多元視角跨域研究模式著重於致病機轉、藥物開發、早期診斷等重大目標方向，深化培養具國際視野並兼具專精領域(尤其是精準醫學)的高階研究人才，提升臺灣相關領域國際地位並加值國家產業。 此外研究中心成員亦來自臺大各學院包括電資學院、生命科學院、生農學院、及公衛學院等，實質執行跨領域合作，有效結合2018年成立的臺大「人工智慧技術暨全幅健康照護聯合研究中心」和2022年成立的兩院級「智慧醫療中心的廣達人工智慧運算使用專區」，成功融合健康大數據與人工智慧技術及優質運算與儲存系統，解決病人隱私、醫療倫理、與數據安全問題，促使臺大醫學院區成為醫療業界典範轉移。配合政府推動發展利基之精準醫學工作項目與行政院BTC會議所建言的「生醫並聯智慧科技開創精準健康新未來(2022)」，研究中心未來發展仍將著重於校內外資源整合，配合既有臺大醫療體系包括卓越臨床研究中心、臺大癌症醫院與竹北生醫園區醫院，以及臺大生醫校園生態系，規劃技術合作之跨領域平台，邁向成為技術領先、具有臺灣乃至於國際競爭力的精準醫學研究中心，攜手各方共創精準醫學的美好未來！